Table 2.
Escitalopram doses and treatment outcomes.
Medication | Range | Mean | |||||||
---|---|---|---|---|---|---|---|---|---|
Escitalopram (mg/day) | 5–20 | 12.5 ± 5.08* | |||||||
Measures | Baseline | 2 week | 4 week | 6 week | 8 week | 12 week | F1 | d.f.2 | p1 |
BDNF levels (ng/ml) | 16.90 ± 3.91* | NA | 16.32 ± 3.17* | NA | 17.08 ± 3.85* | 14.93 ± 3.68* | 2.27 | 1, 45.5 | 0.138 |
CAPS scores | 61.81 ± 14.62* | NA | NA | NA | NA | 28.86 ± 17.91* | 38.61 | 1, 14.8 | < 0.001 |
PCL scores | 56.00 ± 11.96* | 44.81 ± 13.05* | 41.56 ± 12.06* | 37.50 ± 11.45* | 35.87 ± 11.69* | 31.47 ± 13.26* | 70.50 | 1, 78.1 | < 0.001 |
HAM-D scores | 18.19 ± 7.29* | NA | NA | NA | NA | 6.13 ± 4.61* | 57.64 | 1, 14.6 | < 0.001 |
Values are given as mean ± standard deviation.
CAPS: Clinician Administered PTSD Scale; PCL: PTSD Checklist; HAM-D: Hamilton Depression scale; NA: Not Available.
Linear change over time based on mixed model analysis of all available time points.
Denominator degrees of freedom are Satterthwaite estimates from the mixed model, and need not be integer values.